Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

• Status: Recruiting
• Trial end date: 2025-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against Metallo-β-lactamases (MBL) producing Enterobacterales in vivo. The investigators then use CRISPR/Cas9 technology to remove Enterobacteriaceae bacteria resistance and virulence genes

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qianfoshan Hospital
• Treatments: Avibactam; Aztreonam

Criteria

Inclusion Criteria:

• Subjects clinically suspected of infection caused by Enterobacterales

• Subjects with bloodstream infection by MBL-producing Enterobacterales

Exclusion Criteria:

• Infections caused by viruses, fungi, atypical pathogens, and other non-Enterobacteriaceae bacteria

• subjects who are unwilling to enter the research group